Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients.
Revicki
D A
DA
Battelle Medical Technology and Policy Research Center, Washington, D.C. 20024.
Luce
B R
BR
Weschler
J M
JM
Brown
R E
RE
Adler
M A
MA
D000328:Adult; D000359:Aftercare / Q000191:economics; D002908:Chronic Disease; D003024:Clozapine / Q000627:therapeutic use*; D003156:Community Mental Health Services / Q000191:economics; D003362:Cost-Benefit Analysis; D003984:Dibenzazepines / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007902:Length of Stay / Q000191:economics; D008297:Male; D011569:Psychiatric Status Rating Scales; D012017:Referral and Consultation / Q000191:economics; D012559:Schizophrenia / Q000188:drug therapy* / Q000191:economics; D012565:Schizophrenic Psychology
D003984:Dibenzazepines; D003024:Clozapine